Parallel Advisors’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $33.6K | Sell |
596
-29
| -5% | -$1.89K | ﹤0.01% | 2221 |
|
|
2025
Q4 | $50.1K | Buy |
625
+396
| +173% | +$26.6K | ﹤0.01% | 1850 |
|
|
2025
Q3 | $11.2K | Sell |
229
-103
| -31% | -$6.38K | ﹤0.01% | 2494 |
|
|
2025
Q2 | $24.8K | Buy |
332
+74
| +29% | +$4.9K | ﹤0.01% | 2095 |
|
|
2025
Q1 | $16.4K | Buy |
258
+70
| +37% | +$4.76K | ﹤0.01% | 2238 |
|
|
2024
Q4 | $14.7K | Buy |
188
+15
| +9% | +$1.21K | ﹤0.01% | 2275 |
|
|
2024
Q3 | $13.9K | Sell |
173
-11
| -6% | -$889 | ﹤0.01% | 2274 |
|
|
2024
Q2 | $15.2K | Sell |
184
-3
| -2% | -$264 | ﹤0.01% | 2129 |
|
|
2024
Q1 | $16K | Buy |
187
+6
| +3% | +$471 | ﹤0.01% | 2101 |
|
|
2023
Q4 | $15.5K | Sell |
181
-52
| -22% | -$4.5K | ﹤0.01% | 2097 |
|
|
2023
Q3 | $20.9K | Hold |
233
| – | – | ﹤0.01% | 1810 |
|
|
2023
Q2 | $19.8K | Sell |
233
-5
| -2% | -$423 | ﹤0.01% | 1863 |
|
|
2023
Q1 | $19.7K | Sell |
238
-110
| -32% | -$8.9K | ﹤0.01% | 1844 |
|
|
2022
Q4 | $27.4K | Buy |
348
+9
| +3% | +$723 | ﹤0.01% | 1571 |
|
|
2022
Q3 | $25K | Buy |
339
+103
| +44% | +$7.4K | ﹤0.01% | 1584 |
|
|
2022
Q2 | $15K | Buy |
236
+8
| +4% | +$473 | ﹤0.01% | 1805 |
|
|
2022
Q1 | $14K | Buy |
228
+7
| +3% | +$381 | ﹤0.01% | 1866 |
|
|
2021
Q4 | $12K | Sell |
221
-190
| -46% | -$11.6K | ﹤0.01% | 2026 |
|
|
2021
Q3 | $29K | Buy |
411
+253
| +160% | +$16K | ﹤0.01% | 1548 |
|
|
2021
Q2 | $11K | Sell |
158
-5
| -3% | -$354 | ﹤0.01% | 1963 |
|
|
2021
Q1 | $18K | Sell |
163
-2
| -1% | -$247 | ﹤0.01% | 1641 |
|
|
2020
Q4 | $20K | Buy |
165
+32
| +24% | +$3.44K | ﹤0.01% | 1468 |
|
|
2020
Q3 | $12K | Hold |
133
| – | – | ﹤0.01% | 1661 |
|
|
2020
Q2 | $11K | Hold |
133
| – | – | ﹤0.01% | 1674 |
|
|
2020
Q1 | $13K | Hold |
133
| – | – | ﹤0.01% | 1490 |
|
|
2019
Q4 | $15K | Sell |
133
-14
| -10% | -$1.69K | ﹤0.01% | 1546 |
|
|
2019
Q3 | $19K | Buy |
147
+14
| +11% | +$1.78K | ﹤0.01% | 1373 |
|
|
2019
Q2 | $16K | Hold |
133
| – | – | ﹤0.01% | 1379 |
|
|
2019
Q1 | $12K | Hold |
133
| – | – | ﹤0.01% | 1445 |
|
|
2018
Q4 | $13K | Hold |
133
| – | – | ﹤0.01% | 1218 |
|
|
2018
Q3 | $15K | Sell |
133
-12
| -8% | -$1.24K | ﹤0.01% | 1267 |
|
|
2018
Q2 | $13K | Hold |
145
| – | – | ﹤0.01% | 1226 |
|
|
2018
Q1 | $11K | Hold |
145
| – | – | ﹤0.01% | 1228 |
|
|
2017
Q4 | $8K | Hold |
145
| – | – | ﹤0.01% | 1378 |
|
|
2017
Q3 | $8K | Hold |
145
| – | – | ﹤0.01% | 1369 |
|
|
2017
Q2 | $6K | Buy |
145
+16
| +12% | +$657 | ﹤0.01% | 1509 |
|
|
2017
Q1 | $5K | Buy |
+129
| New | +$5.04K | ﹤0.01% | 1491 |
|
Other funds holding HAE
VPM
VCM
RRAM
Parallel Advisors's HAE Position: Q1 2026 in Review
Parallel Advisors reduced its Haemonetics (HAE) stake by 4.6% in Q1 2026, selling an estimated $1.89K and leaving 596 shares worth $33.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2221.
Parallel Advisors first reported a position in HAE in Q1 2017 and has held it in 37 quarters since. The position peaked at $50.1K in Q4 2025. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- Parallel Advisors held 596 shares of Haemonetics worth $33.6K as of Q1 2026.
- Parallel Advisors sold 29 Haemonetics shares in Q1 2026, an estimated $1.89K.
- Haemonetics made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #2221 holding.
- Parallel Advisors first reported a position in Haemonetics in Q1 2017 and has held it in 37 quarters since.
- Parallel Advisors's Haemonetics position peaked at $50.1K in Q4 2025.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.